ArticleFrontiers in pharmacology2021

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells.

Min Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.